Beneficial effects of sunitinib on tumor microenvironment and immunotherapy targeting death receptor5-Reference-Cited by-同舟云学术

Beneficial effects of sunitinib on tumor microenvironment and immunotherapy targeting death receptor5

Published:2018-11-13 Issue:2 Volume:8 Page:e1543526
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Tsukita Yoko¹,Okazaki Tatsuma¹²^ORCID,Ebihara Satoru³,Komatsu Riyo¹,Nihei Mayumi¹,Kobayashi Makoto¹,Hirano Taizou¹,Sugiura Hisatoshi¹,Tamada Tsutomu¹^ORCID,Tanaka Nobuyuki⁴,Sato Yasufumi⁵,Yagita Hideo⁶,Ichinose Masakazu¹

Affiliation:

1. Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan

2. Present address; Department of Physical Medicine and Rehabilitation, Tohoku University Graduate School of Medicine, Sendai, Japan

3. Department of Rehabilitation Medicine, Toho University Graduate School of Medicine, Tokyo, Japan

4. Division of Tumor Immunobiology, Department of Cancer Medical Science, Tohoku University Graduate School of Medicine, Sendai, Japan

5. Department of Vascular Biology, Institute of Development, Aging, and Cancer, Tohoku University, Sendai, Japan

6. Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan

Funder

Ministry of Education, Science and Culture of the Japanese Government

Research Promotion Grant from Toho University Graduate School of Medicine

Research Funding for Longevity Sciences

AMED

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2018.1543526

Reference63 articles.

1. Targeting death-inducing receptors in cancer therapy

2. Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy

3. Eradication of established tumors in mice by a combination antibody-based therapy

4. Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules

5. A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multifunctional PEGylated liposomal-encapsulated sunitinib enhancing autophagy, immunomodulation, and safety in renal cell carcinoma;Journal of Nanobiotechnology;2024-07-31

2. Pericytes: jack-of-all-trades in cancer-related inflammation;Frontiers in Pharmacology;2024-07-17

3. The Role of Oxidative Stress in Tumorigenesis and Progression;Cells;2024-03-02

4. Reprogramming the pancreatic cancer stroma and immune landscape by a silicasome nanocarrier delivering nintedanib, a protein tyrosine kinase inhibitor;Nano Today;2024-02

5. Inhibiting anti-angiogenic VEGF165b activates a miR-17-20a-Calcipressin-3 pathway that revascularizes ischemic muscle in peripheral artery disease;Communications Medicine;2024-01-05